Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/VRTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Read full analysis

Key Stats

  • Market Cap
    $134.06B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $557.96
  • 52W Low
    $376.62
  • Typical Hold Time
    -
  • Enterprise Value
    $128.18B
  • Div Yield
    -
  • Trading Activity
    -
$522.29
52W Low: $376.62
24 Sep 2025
52W High: $557.96
03 Sep 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $376.62 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Clarity Act likely to pass, Coinbase CEO says, promising clearer crypto rules and institutional growth.

Coinbase CEO Brian Armstrong expressed confidence that the Clarity Act, a U.S. federal bill to regulate digital assets, is likely to pass the Senate with broad support from crypto firms and banks. The legislation aims to clarify oversight between the...

Market News
4 hours ago
CNBC
Bullish
news icon
Clarity Act likely to pass, Coinbase CEO says, promising clearer crypto rules and institutional growth.

HIVE Digital appoints Mark Volk to lead global AI revenue growth and surpasses $1M daily revenue in AI and Bitcoin mining.

HIVE Digital Technologies has appointed Mark Volk as Senior Vice President, Revenue at its subsidiary BUZZ HPC to drive global AI infrastructure sales. Volk brings extensive experience from HPE, IBM, and other tech firms to scale BUZZ's GPU-powered A...

Market News
5 hours ago
Newsfile Corp
Bullish
news icon
HIVE Digital appoints Mark Volk to lead global AI revenue growth and surpasses $1M daily revenue in AI and Bitcoin mining.

ZeroRisk raises $10M to expand global cybersecurity services for payment providers.

ZeroRisk, an Irish cybersecurity firm specializing in risk management for payment providers, secured $10 million in a Series A funding round led by MiddleGame Ventures and Elkstone. Founded in 2023, ZeroRisk offers a platform that helps banks and pay...

Market News
5 hours ago
PRNewsWire
Bullish
news icon
ZeroRisk raises $10M to expand global cybersecurity services for payment providers.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $134.06B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $557.96
  • 52W Low
    $376.62
  • Typical Hold Time
    -
  • Enterprise Value
    $128.18B
  • Div Yield
    -
  • Trading Activity
    -
$522.29
52W Low: $376.62
24 Sep 2025
52W High: $557.96
03 Sep 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $376.62 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!